Skip to main content

Table 2 Comparison of outcomes according to the exposure to TNFis

From: Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis

 

Total (N = 450)

TNFi exposed (N = 233)

TNFi not exposed (N = 217)

P value

Incident cardiovascular disease, n (%)

20 (4.44)

6 (2.6)

14 (6.5)

0.046

Duration of follow-up, years, median (IQR)

5.5 (2.9–9.4)

6.3 (3.4–10.2)

4.7 (2.8–8.2)

0.002

Time to events, years, median (IQR)

3.9 (1.8–7.2)

3.3 (2.0–8.4)

4.4 (1.7–7.0)

> 0.999

  1. TNFi tumor necrosis factor inhibitor, ESR erythrocyte sedimentation rate, CRP C-reactive protein